Conditions: Prostate Cancer
Keywords: prostate cancer hormone-resistant prostate cancer recurrent prostate cancer stage IV prostate cancer
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 13
Healthy volunteers: no

Brief summary:
The purpose of this study is to assess the effect of combining abiraterone with medicines that may block some of the ways that cells become resistant to abiraterone. The investigators hope that these combinations of medicines will result in prostrate cancer cells dying.

This study will see if overcoming diseases resistance to abiraterone will restore sensitivity to androgen deprivation therapy.

Detailed description:
Subjects will be either treated on one of the earlier dosing regimens or randomly assigned to one of two groups or ARMs of this study.

ARM A will receive Abiraterone with ABT-263.

ARM B will receive Abiraterone with both ABT-263 and Hydroxychloroquine

In the beginning of the study a total of 18 patients may get one of three dose levels. A total of nine (9) patients per each arm will be started at a low dose and given increasing doses if no side effects are seen. In this part of the study three patients will be enrolled at each dose level for each individual arm starting with Arm A followed by Arm B.

Arms:
arm 1: Abiraterone with ABT-263 arm 2: Abiraterone with both ABT-263 and Hydroxychloroquine

Interventions: intervention 1: Abiraterone intervention 2: ABT-263 intervention 3: Hydroxychloroquine
Intervention descriptions: intervention 1: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine) intervention 2: ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine) intervention 3: ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)

Protocol document: